This forum is for the discussion of anything to do with Prostate Cancer. There are only four rules:
No fundraisers, no commercials (although it is OK to recommend choices of treatment or medical people based on your personal research; invitations to participate in third-party surveys are also acceptable, provided there is no compensation to YANA);
No harvesting e-mail addresses for Spam;
No insults or flaming - be polite and respectful at all times and understand that there may be a variety of points of view, all of which may have some validity;
Opinions are OK, but please provide as much factual evidence as possible for any assertions that you are making
Failure to abide by these simple rules will result in the immediate and permanent suspension of your posting privileges.
Since this is an International Forum, please specify your location in your post.
Re: Drug companies influences on docs and disclosure laws (from Dr. William Douglas email reports)
Hello everyone,
Terry, this might be slightly off topic, but further to your comment about Avodart and Flomax, on 1st August, 2011, Dutasteride with tamsulosin in a fixed dose combination was listed on the PBS under the name Duodart. For non-Aussies, PBS is the Pharmaceutical Benefits Scheme here in OZ.
Previously, Avodart could only be prescribed on the PBS (by a urologist) in combination with an alpha-blocker. So it seemed inevitable that Duodart would emerge, being 0.5 mg of dutasteride (Avodart) combined with 0.4 mg of tamsulosin (Flomax) in the same capsule.
